Serial Passage

Part of Vaccines

Repeatedly transferring a pathogen through foreign hosts to produce attenuated strains for live vaccine use.

Why This Matters

Serial passage is the most historically proven method for producing live attenuated vaccines. By forcing a pathogen to grow repeatedly in conditions that are unfamiliar — a different animal species, an unusual tissue type, a suboptimal temperature — natural selection progressively weakens its ability to cause disease in its original host while it adapts to the new environment. The result is a pathogen that is alive, replicating, and immunogenic, but no longer dangerous.

Every major live attenuated vaccine in history was produced through some form of serial passage. BCG tuberculosis vaccine: 230 passages over 13 years on ox bile-glycerol-potato medium. Yellow fever 17D vaccine: hundreds of passages through mouse brain and chicken embryo tissue. Oral polio Sabin strains: passage through monkey kidney cells and mouse brain. The concept is universal; the specific conditions vary by organism.

In a rebuilding society, serial passage is a demanding but achievable technique. It requires a suitable alternate host system, careful monitoring, time, and meticulous record-keeping. The investment is substantial — but the result is a self-replicating vaccine that can produce robust, long-lasting immunity from a single dose.

Biological Basis

Why passage attenuates: Pathogens are evolutionarily optimized for their natural host. When transferred to a novel host or tissue, they encounter different cell receptors, immune responses, and metabolic environments. Organisms with mutations that allow better growth in the new environment — and that happen to reduce virulence in the original host — are selected.

This is not directed evolution; it is blind selection. Many mutations in the new host environment are neutral or harmful for human virulence. Over many generations, the organism accumulates these mutations through random mutation and selection pressure in the new environment.

Key point: Attenuation through serial passage involves multiple independent genetic changes. This makes reversion to full virulence difficult (requiring simultaneous back-mutation at multiple sites) though not impossible.

When does a pathogen become attenuated? There is no fixed answer. The pathogen’s virulence in test animals is measured periodically throughout the passage series. Virulence typically declines gradually, often with periods of plateau, then further decline. The decision to use a strain as vaccine requires documented stability of attenuation — not just one measurement but consistency across several serial tests.

Passage Systems

Different passage systems are suitable for different pathogens.

Laboratory animals: Small mammals (mice, rabbits, guinea pigs) are the most accessible alternate host system. For organisms with a natural human host, passage through mice or rabbits represents a significant environmental shift.

Examples:

• Rabies virus: Pasteur’s serial desiccation and passage through rabbit spinal cord. Each passage in rabbit neural tissue reduces virulence for dogs and humans.
• BCG precursor (M. bovis): passage in cattle bile-supplemented media was the key environmental stressor.

Embryonated eggs: The developing embryo inside a fertilized egg provides a warm, accessible environment supporting growth of many viruses. Egg passage was used for yellow fever, influenza, and other viral vaccines.

Advantages: Consistent, available from any maintained flock; free from mammalian immune responses that might clear the virus too quickly.

Disadvantages: Eggs have their own proteins that can contaminate the final product and cause reactions in egg-allergic individuals.

Suboptimal temperature passage: Some organisms attenuate when passaged at temperatures below their optimal growth temperature. Live attenuated influenza vaccine (LAIV) is cold-adapted — passaged at 25°C until adapted. At this temperature it grows well; at 37°C (human body temperature in lower airways) it grows poorly. The result is a virus that replicates in the cooler nasal passages but not in the warm lower respiratory tract — causing mild upper respiratory infection rather than pneumonia.

Practical application: If temperature control is available, serial passage at 5-10°C below optimal temperature is worth exploring for respiratory pathogens.

Practical Protocol for Serial Passage

Prerequisites:

• Pure culture of target pathogen
• Suitable host system (animal colony, embryonated eggs, or tissue culture)
• Temperature-controlled incubation
• Sterile technique
• Storage capability for passage stocks
• Test animals for virulence monitoring

Step 1: Establish baseline virulence Before beginning passage:

1. Inoculate a group of 5+ test animals with a defined dose of the original pathogen.
2. Document disease signs and mortality.
3. This is passage 0 virulence — the comparison standard for all subsequent testing.

Step 2: Initiate passage series

1. Inoculate first alternate host with pathogen sample.
2. Harvest after defined incubation period:
   • For animals: collect target tissue (lung for respiratory pathogen, nerve tissue for neurotropic pathogen, blood for systemic pathogen) at peak of infection or before animal death.
   • For eggs: collect allantoic fluid or specific membrane extract after appropriate incubation.
3. Make 1:10 to 1:100 dilution of harvested material in sterile saline or broth.
4. Inoculate second host with diluted material.
5. Record: passage number, date, host, inoculation route, dose, harvest time, signs observed.

Step 3: Monitor virulence at intervals Test virulence in susceptible test animals at passage 5, 10, 20, 30, 50, and then every 25-50 passages:

1. Inoculate test animals (same species as final intended safety test) with defined dose from current passage stock.
2. Monitor for 21 days.
3. Record disease severity (symptom scoring), weight loss, mortality.
4. Compare to passage 0 baseline.

Step 4: Determine stability of attenuation When test animals show substantially reduced or absent disease:

1. Continue passaging for 20-50 more passages while monitoring.
2. Assess consistency: is virulence stably reduced or does it fluctuate?
3. Perform back-passage test: inoculate highly susceptible animals with attenuated strain and re-passage through those animals 3-5 times. If virulence returns easily, attenuation is not stable.
4. True stable attenuation typically involves at least 3-5 independent mutations — demonstrated by genetic instability being low across back-passage.

Step 5: Establish master seed Once stable attenuation is confirmed:

1. Take a defined passage number as the master seed lot.
2. Prepare multiple vials (glycerol stock or lyophilized).
3. Assign a passage number designation (e.g., “Strain X, passage 47”).
4. All future production uses material derived from the master seed.
5. Never passage the master seed further — it is the reference standard.

Step 6: Safety and efficacy testing Before human use:

1. Safety test: inoculate test animals at 10× intended human dose. Observe 21 days. No unacceptable disease.
2. Potency test: vaccinate animals; challenge with virulent parent strain. Protection must exceed defined threshold.
3. Genetic stability test: passage material from master seed through 5 additional animal passages; re-test virulence.

Record-Keeping for Serial Passage

Complete records are not optional — they are the scientific basis for the safety claim.

Passage record (one entry per passage):

Field	Record
Passage number
Date
Host species and number
Inoculation route
Dose (volume and dilution)
Signs in host during incubation
Harvest date
Harvest tissue/fluid
Virulence test at this passage?	Yes/No
Virulence test result	Disease score
Storage location and conditions
Operator

Storage of passage stocks:

• Save at least 5 aliquots of material from every virulence-tested passage.
• Store at −20°C in glycerol stock (50% v/v) if deep freeze is available; at 4°C in glycerol if not.
• Label with passage number, date, and organism.
• These stored aliquots allow recovery from contamination, comparison of different passage levels, and verification of results.

When Serial Passage Fails

Not all pathogens respond well to serial passage attenuation:

• Some organisms do not attenuate — they maintain virulence through many passages
• Some organisms die out in the new host rather than adapting
• Some organisms attenuate but revert quickly (unstable attenuation)
• Some organisms cannot be grown in available host systems

When serial passage fails, consider:

• Different host system (different animal species, different tissue)
• Temperature-based selection instead of host switching
• Chemical attenuation instead of live attenuation
• Killed vaccine preparation as an alternative
• Identifying naturally occurring related organisms (see Related Organisms)

Serial passage is powerful but not universal. The practitioner who understands the principle can adapt it; the one who only follows protocol fails when the protocol fails.